Dr Paxton Loke

Dr Paxton Loke

Details

Role Research Clinician

Top Publications

  • Cheng, DR, Clothier, HJ, Morgan, HJ, Roney, E, Shenton, P, Cox, N, Jones, BO, Schrader, S, Crawford, NW, Buttery, JP, et al. Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12–17-year olds in Victoria, Australia. BMJ Paediatrics Open 6(1) : e001472 2022
    view publication
  • Loke, P, Hsiao, K, Lozinsky, AC, Ashley, SE, Lloyd, M, Pitkin, S, Axelrad, CJ, Jayawardana, KS, Tey, D, Su, EL, et al. Probiotic peanut oral immunotherapy is associated with long‐term persistence of 8‐week sustained unresponsiveness and long‐lasting quality‐of‐life improvement. Clinical & Experimental Allergy 52(6) : 806 -811 2022
    view publication
  • Hsiao, K, Ponsonby, A, Ashley, S, Lee, CYY, Jindal, L, Tang, MLK, Loke, P, Axelrad, C, Pitkin, S, Robinson, M, et al. Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy in children with peanut allergy. Clinical & Experimental Allergy 52(6) : 735 -746 2022
    view publication
  • Loke, P, Orsini, F, Lozinsky, AC, Gold, M, O'Sullivan, MD, Quinn, P, Lloyd, M, Ashley, SE, Pitkin, S, Axelrad, C, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. The Lancet Child & Adolescent Health 6(3) : 171 -184 2022
    view publication
  • Lloyd, M, Loke, P, Ashley, S, Lozinsky, A, Orsini, F, Gold, M, O'Sullivan, M, Prescott, S, Allen, K, Pitkin, S, et al. Health-related quality of life outcomes in a Phase 2b Randomized Trial evaluating the effectiveness and safety of Probiotic Peanut Oral Immunotherapy. Journal of Allergy and Clinical Immunology 149(2) : ab317 2022
    view publication

Page 1 of 9